Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) CFO Sells $673,733.68 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CFO Bruce Jacobs sold 7,576 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $88.93, for a total value of $673,733.68. Following the completion of the transaction, the chief financial officer owned 237,483 shares of the company’s stock, valued at approximately $21,119,363.19. The trade was a 3.09% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Kymera Therapeutics Trading Down 0.0%

KYMR stock opened at $83.49 on Friday. The firm has a market cap of $6.82 billion, a P/E ratio of -22.69 and a beta of 2.20. Kymera Therapeutics, Inc. has a 12-month low of $19.44 and a 12-month high of $103.00. The stock’s 50 day simple moving average is $78.80 and its 200 day simple moving average is $66.80.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The firm had revenue of $2.87 million for the quarter, compared to the consensus estimate of $14.80 million. During the same quarter last year, the business earned ($0.88) earnings per share. The business’s revenue for the quarter was down 60.8% compared to the same quarter last year. On average, research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Institutional Investors Weigh In On Kymera Therapeutics

A number of hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Kymera Therapeutics by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock worth $849,000 after buying an additional 1,833 shares in the last quarter. Millennium Management LLC raised its stake in Kymera Therapeutics by 340.4% during the 1st quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock valued at $13,972,000 after acquiring an additional 394,562 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Kymera Therapeutics by 121.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock worth $24,535,000 after acquiring an additional 491,737 shares during the period. PNC Financial Services Group Inc. boosted its position in Kymera Therapeutics by 506.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after acquiring an additional 770 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Kymera Therapeutics by 5.2% in the second quarter. Geode Capital Management LLC now owns 1,193,112 shares of the company’s stock worth $52,075,000 after purchasing an additional 59,347 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on KYMR shares. Leerink Partners increased their price objective on shares of Kymera Therapeutics from $70.00 to $118.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. UBS Group upped their target price on Kymera Therapeutics from $90.00 to $128.00 and gave the company a “buy” rating in a report on Tuesday. Bank of America raised their price target on Kymera Therapeutics from $71.00 to $112.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Jefferies Financial Group upped their price objective on Kymera Therapeutics from $73.00 to $122.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $119.50.

Kymera Therapeutics News Summary

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: HC Wainwright trimmed near‑term loss forecasts (small EPS improvements across Q1–Q4 2026), kept a “Buy” rating and reiterated a $134 price target — this reinforces constructive analyst sentiment and supports buying interest. Read More.
• Positive Sentiment: UBS and several peers have raised price targets (UBS to $128, Barclays/Oppenheimer/Mizuho also higher), signaling consensus analyst optimism around Kymera’s pipeline progress as a medium‑term catalyst. Read More.
• Positive Sentiment: Another outlet reported a price‑target bump to $100 — additional upward target revisions help underpin sentiment even as valuation remains tied to clinical milestones. Read More.
• Positive Sentiment: Coverage highlights a healthy cash runway (~$1.6B reported) and upcoming program milestones (KT‑579 data in 2H26; KT‑621 Phase 2b readouts in 2027) that are the primary value drivers for this clinical‑stage biotech. Read More.
• Neutral Sentiment: Technical/contextual note — KYMR is trading above its 200‑day moving average with elevated volatility (beta ~2.2); analyst average targets remain well above current levels, which can amplify momentum in either direction. Read More.
• Negative Sentiment: Large director sale: Director Bruce Booth sold 81,866 shares (~$7.38M at ≈$90), a material single‑day disposal that can be perceived as profit‑taking and may cap short‑term upside. Read More.
• Negative Sentiment: Multiple senior insiders (CFO Bruce Jacobs, COO Jeremy Chadwick, Jared Gollob and others) disclosed sales across March 2–4 at roughly $85–$89, each trimming holdings by a few percent — repeated insider selling increases short‑term supply and investor caution. Read More.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.